RIXUBIS Drug Use-Result Survey (Japan)

Baxalta

Status: Completed

Conditions: Hemophilia B

Treatments: Biological: RIXUBIS

Study type: Observational

Funder types: Industry

Identifiers

NCT02937831

251601

Details and patient eligibility

About

The purpose of this survey is to understand the following items observed in the actual clinical use of RIXUBIS.

1. Unexpected adverse drug reactions
2. Occurrence of adverse drug reactions in the actual clinical use
3. Factors that may affect safety and effectiveness
4. Occurrence of Factor IX (FIX) inhibitor development in patients with coagulation FIX deficiency
5. Safety and effectiveness for hemophilia B patients who received routine prophylactic therapy, on-demand therapy and perioperative therapy

Enrollment: 6 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hemophilia B scheduled to receive treatment with RIXUBIS

Exclusion criteria

• Patients not administered RIXUBIS

Trial design

6 participants in 1 patient group

All Study Participants

Treatment:

Biological: RIXUBIS